Trial Profile

A placebo-controlled, dose-ranging, randomized Phase 2 study of ALPN 303 in systemic lupus erythematosus (SLE) and potentially additional autoantibody-related diseases

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 According to an Alpine Immune Sciences media release, the company plans to initiate this study in 2H 2024.
23 Mar 2023 According to an Alpine Immune Sciences media release, the company plans to launch this study in mid-2024, based on enabling data from the RUBY-3 and RUBY-4 studies.
14 Nov 2022 According to an Alpine Immune Sciences media release, the company presented broad development plan including this study at the R&D Day on Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com